July 25 (Reuters) - Anglo-Swedish drugmaker AstraZeneca ( AZN )
on Thursday raised its sales and profit forecast for
2024 and topped analyst expectations for second-quarter revenue,
buoyed by demand for its therapies for cancer and rare diseases.